ProFibrix Closes $11M Series B

8/24/09

Netherlands-based ProFibrix, which has a Seattle subsidiary, announced today it has raised $11 million in Series B funding, led by new investor Gilde Healthcare Partners and including existing investor Index Ventures. ProFibrix was founded in 2004 and makes a dry powder topical tissue sealant that stops bleeding during or after surgery. The product, called Fibrocaps, is currently in a clinical trial in the Netherlands. ProFibrix plans to submit an Investigational New Drug Application to the FDA in the first half of next year.

Gregory T. Huang is Xconomy's Deputy Editor, National IT Editor, and the Editor of Xconomy Boston. You can e-mail him at gthuang@xconomy.com or call him at 617-252-7323. Follow @

By posting a comment, you agree to our terms and conditions.